Patents Examined by Karlheinz R. Skowronek
  • Patent number: 11725248
    Abstract: The present invention provides methods of determining a survival predictor score of a subject having mantle cell lymphoma (MCL). The present invention also provides methods of predicting the survival outcome of a subject having MCL and provides methods of selecting a treatment for a subject having MCL.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: August 15, 2023
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, British Columbia Cancer Agency Branch, Julius-Maximilians-University of Würzburg, Oregon Health & Science University, Hospital Clinic de Barcelona, Universitat de Barcelona, Oslo University Hospital HF, The Cleveland Clinic Foundation, Mayo Foundation for Medical Education and Research
    Inventors: Louis M. Staudt, David William Scott, George W. Wright, Andreas Rosenwald, Pau Abrisqueta, Rita Braziel, Elias Campo Guerri, Wing C. Chan, Joseph M. Connors, Jan Delabie, Diego Villa, Kai Fu, Randy D. Gascoyne, Timothy Greiner, Elaine S. Jaffe, Pedro Jares, Anja Mottok, German Ott, Lisa M. Rimsza, Graham Slack, Dennis Weisenburger, Erlend B. Smeland, James Robert Cook
  • Patent number: 11275557
    Abstract: First sensor data may be acquired from a first galvanic skin response sensor monitoring a first user. Second sensor data may be acquired from a second galvanic skin response sensor monitoring a second user. At least one programmable processor may generate a compatibility score between the first user and the second user. The generating may include executing a compatibility algorithm to generate the compatibility score based at least on a comparison of at least one type of response contained in the first sensor data and the second sensor data. A client device may generate an electronic indication of the compatibility score.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: March 15, 2022
    Assignee: ONTOLEAD, INC.
    Inventors: Firoozeh Motamedi, Shahrokh Yadegari
  • Patent number: 11234955
    Abstract: The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: February 1, 2022
    Assignee: Del Mar Pharmaceuticals (BC) Ltd.
    Inventors: Dennis M. Brown, Jeffrey Bacha, Sandra Dunn
  • Patent number: 11195596
    Abstract: Embodiments of techniques for analyzing one or more genomic regions of a genome of an organism. Data about a genomic region may be analyzed to determine an information content of the genomic region, which may indicate an amount of information provided by the genomic region. The data about the genomic region may be or include data identifying a chromatin state for the genomic region. A chromatin state may be one of a set of chromatin states that each define a different set of one or more chromatin characteristics. Chromatin characteristics may be structural and/or functional features of genomic regions. A chromatin state of a genomic region may be determined from, and describe, the genomic region such that when a genomic region has a set of one or more chromatin characteristics, a chromatin state associated with that combination of one or more chromatin characteristics is identified for the genomic region.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: December 7, 2021
    Assignee: Massachusetts Institute of Technology
    Inventor: Wouter Meuleman
  • Patent number: 11175287
    Abstract: A biometric device, comprising a solid support suitable for receiving biological material and for dry storing that material at room temperature the device further comprising a circuit including means for two way radio frequency communication and including writable data storage. A processing method for such biometric devices, the method including the steps of: a) identifying said device by means of RF communication; b) extracting at least a portion of the biological material from the solid support of the identified device; c) analysing the extracted biological material to obtain biometric data indicative of the biological material; and d) writing said biometric data to the data storage of the biometric device.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: November 16, 2021
    Inventors: Jeffrey Kenneth Horton, Peter James Tatnell, Samantha Jane Ogden, Michael John Smith, Leonard Goren, Steven Pepe, Samit Langar, Vincent Francis Pizzi, Craig Robinson
  • Patent number: 11119033
    Abstract: A conformation analysis device and analysis method with which discrimination can be achieved even if there is a subtle difference in a conformational structure, a given molecule can be processed in a unified manner, and large-scale computer processing can be performed, and a conformational notation device and notation method with which even in the case where a conformation cannot be uniquely determined if a rule in accordance with the IUPAC Nomenclature is followed, the conformation can be uniquely notated, a given molecule can be processed in a unified manner, and large-scale computer processing can be performed, are provided.
    Type: Grant
    Filed: April 22, 2009
    Date of Patent: September 14, 2021
    Inventors: Hiroshi Izumi, Atsushi Ogata, Kazuyuki Takeo, Hideki Kobayashi
  • Patent number: 11091809
    Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test identifies cancer subtypes that have an up-regulation or a down-regulation in biomarker expression related to angiogenesis and vascular development. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any anti-angiogenic agent. This test may be used in different cancer types and with different drugs that directly or indirectly affect angiogenesis or angiogenesis signalling. In addition, the present invention may be used as a prognostic indicator for certain cancer types. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: August 17, 2021
    Assignee: Almac Diagnostic Services Limited
    Inventors: Denis Paul Harkin, Fionnuala Patterson, Claire Trinder, Eamonn J. O'Brien, Caroline Michie, Charlie Gourley, Laura A. Hill, Katherine E. Keating, Jude O'Donnell, Max Bylesjo, Steve Deharo, Vitali Proutski, Richard Kennedy, Timothy Davison, Andreas Winter, Andrena McCavigan
  • Patent number: 10854326
    Abstract: A method for predicting drug concentration levels includes receiving at least one subject characteristic of the subject, and executing a full body circulation model by: determining a first concentration of the drug in a first blood flow entering a first organ determining a second concentration of the drug in the first organ, determining a third concentration of a drug in a third blood flow entering a second organ, the third blood flow downstream of the first organ, and determining, using the second organ model a fourth concentration of the drug in the second organ.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: December 1, 2020
    Assignee: VERISIM LIFE INC.
    Inventor: Jyotika Varshney
  • Patent number: 10766939
    Abstract: The present invention relates to amylin analogs and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogs have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: September 8, 2020
    Assignee: Zealand Pharma A/S
    Inventors: Rasmus Just, Oliver Demmer, Lise Giehm, Jesper Sloth Villadsen, Henrik Munch, Jesper Mosolff Mathiesen, Jolanta Skarbaliene, Maria Deryabina, Dieter Wolfgang Hamprecht
  • Patent number: 10670600
    Abstract: The invention relates to isolated peptides and chimeric polypeptides derived from Saposin A that have anti-angiogenic activity. These peptides are small, consisting essentially of at least 10 consecutive amino acid residues from the 31st-50th amino acid residue of Saposin A. The invention also relates to the use of these isolated peptides and chimeric polypeptides in compositions for the treatment, prevention, and inhibition of angiogenesis-related diseases and disorders such as cancer and cancer metastasis.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: June 2, 2020
    Assignee: Children's Medical Center Corporation
    Inventor: Randolph Watnick
  • Patent number: 10647747
    Abstract: The present invention relates to a compound of the Formula (I)): or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, and hair loss.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: May 12, 2020
    Assignee: S&T GLOBAL INC.
    Inventors: Zhuang Su, Zhengyu Long, Zhennian Huang, Suizhou Yang
  • Patent number: 10604779
    Abstract: Disclosed is a highly efficient method for production of highly pure mutant-type human erythropoietin. The method is for production of mutant-type human erythropoietin, in which a transformed mammalian cell is allowed to produce the mutant-type human erythropoietin, and the supernatant of the culture is subjected to hydrophobic column chromatography, multimodal anion exchange column chromatography, anion exchange column chromatography, phosphate group affinity column chromatography, and gel filtration column chromatography, in this order.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: March 31, 2020
    Inventors: Shinji Kakimoto, Miroslav Matev, Tsuyoshi Fukui, Yukichi Hatano, Junya Tani, Kazutoshi Mihara, Kenichi Takahashi, Atsushi Sugimura
  • Patent number: 10598667
    Abstract: The present invention provides kits and methods for detecting peptides that change of the fluorescence of dyes upon binding to the dye. In addition, the invention provides methods for identifying said peptides.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: March 24, 2020
    Inventors: Kit S. Lam, Lin Tian, Sara Ahadi, Ruiwu Liu
  • Patent number: 10577405
    Abstract: Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: March 3, 2020
    Assignee: Mederis Diabetes LLC
    Inventor: John J. Nestor
  • Patent number: 10568992
    Abstract: The present invention relates to the production of endothelialized matrices and materials from immature endothelial cells using substrates to which particular peptides have been grafted. The resultant substrates can be used to capture and support immature endothelial cells. Further, the methods and compositions of the present invention provide viable cell delivery platforms that allow for production and provision of endothelialized medical devices and implants, including vascular grafts, stents, shunts, and valves, endothelialized surfaces and channels for in vitro testing devices, including microfluidic chips, and materials that support vascularization such as for use in engineered tissues. The present invention includes novel methods required for the successful production of cellularized substrates, systems and components used for the same, and methods of using the resultant cell and tissue compositions.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: February 25, 2020
    Assignee: Auburn University
    Inventors: Elizabeth A. Lipke, Wen Jun Seeto
  • Patent number: 10570189
    Abstract: The present disclosure provides muteins of FVIII to which a biocompatible polymer may be attached to increase the circulatory half-life of the muteins, as well as conjugates of such muteins and biocompatible polymers.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: February 25, 2020
    Assignee: PFIZER INC.
    Inventors: James Apgar, Debra Pittman, Mark Stahl, Laura Lin, Justin Cohen
  • Patent number: 10570188
    Abstract: Herein is reported a method for the production of a polypeptide that is biologically active as n-mer comprising a nucleic acid encoding a fusion polypeptide according to the following formula (Bn-CSo-Is-CSp-FC-CSq-ItCSr-Bm)u, wherein B denotes a polypeptide that is biologically active as n-mer and forms non-defined aggregates/multimers upon expression in the absence of a fused Fc-region, FC denotes a heavy chain Fc-region polypeptide, CS denotes a cleavage site, and I denotes an intervening amino acid sequence, wherein FC does not substantially bind to an Fc-receptor, recovering the fusion polypeptide from the cell or the cultivation medium, optionally cleaving the fusion polypeptide with a protease, and thereby producing a polypeptide that is biologically active as n-mer and forms non-defined aggregates/multimers upon expression in the absence of a fused Fc-region.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: February 25, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Johannes Auer, Martin Bader, Stefan Dengl, Stefan Lorenz, Stefan Seeber
  • Patent number: 10562952
    Abstract: Chimeric antigen receptors (CARs) that specifically bind to and immunologically recognize CD276 are disclosed. Related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: February 18, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Crystal L. Mackall, Yongzhi Karen Cui
  • Patent number: 10555988
    Abstract: The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: February 11, 2020
    Assignee: Chain Antimicrobials Oy
    Inventors: Tejesvi Mysore Vishakante Gowda, Anna Maria Pirttilä
  • Patent number: 10556924
    Abstract: The present invention relates to a novel process for the preparation of Pasireotide of formula 11 [Cyclo [Phe-{4-(OCO—NH—CH2—CH2—NH2)) Pro}-Phg-DTrp-Lys-Tyr(Bzl)]]. The invention also relates to a novel intermediate compound of formula 8 and process thereof which is used for preparation of compound of formula 11.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: February 11, 2020
    Inventors: Manik Reddy Pullagurla, Radha Nagarapu, Jagadeesh Babu Rangisetty